R280T mutation of p53 gene promotes proliferation of human glioma cells through GSK-3β/PTEN pathway

Neuroscience Letters

Volumn 529, Issue 1, 2012, Pages 60-65

  Lin, Chenli ^a   Liang, Yinji ^a   Zhu, Huili ^a   Zhang, Jijun ^a   Zhong, Xueyun ^a  

^a MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

Author keywords

GSK 3 PTEN pathway; Human glioma; R280T mutation of p53 gene; SWO 38 cells

Indexed keywords

BETA CATENIN; GENOMIC DNA; GLYCOGEN SYNTHASE KINASE 3BETA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; RNA; WNT PROTEIN;

ARTICLE; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CODON; CONTROLLED STUDY; DNA BASE COMPOSITION; EXON; GENE MUTATION; GENE OVEREXPRESSION; GLIOMA CELL; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

CELL LINE, TUMOR; CELL PROLIFERATION; GLIOMA; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MUTATION; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84867712087     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2012.09.022     Document Type: Article

References (30)

1. Al-Khouri A.M., Ma Y., Togo S.H., Williams S., Mustelin T. Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta. Journal of Biological Chemistry 2005, 280:35195-35202.
2. Chen J., McKey R.M., Parada L.F. Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell 2012, 149:36-47.
3. Concin N., Zeillinger C., Tong D., Stimpfl M., Konig M., Printz D., Stonek F., Schneeberger C., Hefler L., Kainz C., Leodolter S., Haas O.A., Zeillinger R. Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines. Breast Cancer Research and Treatment 2003, 79:37-46.
4. Cooper M.J., Haluschak J.J., Johnson D., Schwartz S., Morrison L.J., Lippa M., Hatzivassiliou G., Tan J. p53 Mutations in bladder carcinoma cell lines. Oncology Research 1994, 6:569-579.
5. Doble B.W., Woodgett J.R. GSK-3: tricks of the trade for a multi-tasking kinase. Journal of Cell Science 2003, 116:1175-1186.
6. Fan Q.W., Weiss W.A. Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. Current Topics in Microbiology and Immunology 2010, 347:279-296.
7. Forde J.E., Dale T.C. Glycogen synthase kinase 3: a key regulator of cellular fate. Cellular and Molecular Life Sciences 2007, 64:1930-1944.
8. Frankel R.H., Bayona W., Koslow M., Newcomb E.W. p53 Mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency. Cancer Research 1992, 52:1427-1433.
9. Halevy O., Michalovitz D., Oren M. Different tumor-derived p53 mutants exhibit distinct biological activities. Science 1990, 250:113-116.
10. Kato H., Kato S., Kumabe T., Sonoda Y., Yoshimoto T., Han S.Y., Suzuki T., Shibata H., Kanamaru R., Ishioka C. Functional evaluation of p53 and PTEN gene mutations in gliomas. Clinical Cancer Research 2000, 6:3937-3943.
11. Li Y., Guessous F., Kwon S., Kumar M., Ibidapo O., Fuller L., Johnson E., Lal B., Hussaini I., Bao Y., Laterra J., Schiff D., Abounader R. PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations. Cancer Research 2008, 68:1723-1731.
12. Ma S., Liu S., Huang Q., Xie B., Lai B., Wang C., Song B., Li M. Site-specific phosphorylation protects glycogen synthase kinase-3beta from Calpain-mediated truncation of its N and C termini. Journal of Biological Chemistry 2012, 287:22521-22532.
13. Mishra R. Glycogen synthase kinase 3 beta: can it be a target for oral cancer. Molecular Cancer 2010, 9:144.
14. Nabeya Y., Loganzo F., Maslak P., Lai L., de Oliveira A.R., Schwartz G.K., Blundell M.L., Altorki N.K., Kelsen D.P., Albino A.P. The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. International Journal of Cancer 1995, 64:37-46.
15. Olivier M., Hussain S.P., Caron de Fromentel C., Hainaut P., Harris C.C. TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Scientific Publications 2004, 247-270.
16. Ribeiro J.C., Barnetson A.R., Fisher R.J., Mameghan H., Russell P.J. Relationship between radiation response and p53 status in human bladder cancer cells. International Journal of Radiation Biology 1997, 72:11-20.
17. Sigal A., Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Research 2000, 60:6788-6793.
18. Situ R., Wang H.H., Wang J.H., He L.P., Zhu X.L., Ou W.F. Establishement of human brain malignant glioma cell line (SWO-38) and observation of its biologic properties. Chinese Journal of Cancer 1987, 6:235-238.
19. Solomon H., Madar S., Rotter V. Mutant p53 gain of function is interwoven into the hallmarks of cancer. Journal of Pathology 2011, 225:475-478.
20. Sun Y., Hegamyer G., Cheng Y.J., Hildesheim A., Chen J.Y., Chen I.H., Cao Y., Yao K.T., Colburn N.H. An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:6516-6520.
21. Sun Y., Nakamura K., Wendel E., Colburn N. Progression toward tumor cell phenotype is enhanced by overexpression of a mutant p53 tumor-suppressor gene isolated from nasopharyngeal carcinoma. Proceedings of the National Academy of Sciences of the United States of America 1993, 90:2827-2831.
22. Trotman L.C., Pandolfi P.P. PTEN and p53: who will get the upper hand?. Cancer Cell 2003, 3:97-99.
23. Vazquez F., Ramaswamy S., Nakamura N., Sellers W.R. Phosphorylation of the PTEN tail regulates protein stability and function. Molecular and Cellular Biology 2000, 20:5010-5018.
24. Vikhanskaya F., Lee M.K., Mazzoletti M., Broggini M., Sabapathy K. Cancer-derived p53 mutants suppress p53-target gene expression - potential mechanism for gain of function of mutant p53. Nucleic Acids Research 2007, 35:2093-2104.
25. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature 2000, 408:307-310.
26. Vousden K.H., Lu X. Live or let die: the cell's response to p53. Nature Reviews Cancer 2002, 2:594-604.
27. Watcharasit P., Bijur G.N., Zmijewski J.W., Song L., Zmijewska A., Chen X., Johnson G.V., Jope R.S. Direct, activating interaction between glycogen synthase kinase-3beta and p53 after DNA damage. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:7951-7955.
28. Yang Y., Feng L.Q., Zheng X.X. Microtubule and kinesin/dynein-dependent, bi-directional transport of autolysosomes in neurites of PC12 cells. International Journal of Biochemistry and Cell Biology 2011, 43:1147-1156.
29. Yang Y., Fukui K., Koike T., Zheng X. Induction of autophagy in neurite degeneration of mouse superior cervical ganglion neurons. European Journal of Neuroscience 2007, 26:2979-2988.
30. Zalcenstein A., Stambolsky P., Weisz L., Muller M., Wallach D., Goncharov T.M., Krammer P.H., Rotter V., Oren M. Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants. Oncogene 2003, 22:5667-5676.